Intellia Therapeutics (NTLA) to Release Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect Intellia Therapeutics to post earnings of ($1.32) per share and revenue of $8.10 million for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Intellia Therapeutics Trading Down 0.7 %

NTLA traded down $0.08 during trading on Friday, hitting $12.17. The stock had a trading volume of 4,444,535 shares, compared to its average volume of 2,901,163. The firm has a market cap of $1.24 billion, a PE ratio of -2.24 and a beta of 1.80. Intellia Therapeutics has a 12 month low of $8.96 and a 12 month high of $34.87. The company has a 50 day simple moving average of $11.03 and a 200-day simple moving average of $15.98.

Analysts Set New Price Targets

NTLA has been the topic of several recent analyst reports. Barclays dropped their price target on Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating on the stock in a research report on Friday, November 8th. Morgan Stanley downgraded Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Wells Fargo & Company cut their price target on Intellia Therapeutics from $70.00 to $60.00 and set an "overweight" rating for the company in a report on Friday, January 10th. The Goldman Sachs Group decreased their price objective on Intellia Therapeutics from $19.00 to $12.00 and set a "neutral" rating on the stock in a report on Tuesday, January 14th. Finally, StockNews.com raised Intellia Therapeutics to a "sell" rating in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Intellia Therapeutics has an average rating of "Moderate Buy" and an average price target of $48.71.

Insider Activity

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares of the company's stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 29,000 shares of company stock worth $352,551 in the last 90 days. Corporate insiders own 3.20% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.